Thomas Klein

Empagliflozin, a novel selective sodium glucose cotransporter‐2 (SGLT‐2) inhibitor: characterisation and comparison with other SGLT‐2 inhibitors

Rolf Grempler, Leo Thomas, Matthias Eckhardt et al. · Diabetes Obesity and Metabolism · 2011 · 603 citations

Medicine, Pharmacokinetics, Pharmacology +17

Randomized controlled trial of mindfulness‐based stress reduction (MBSR) for survivors of breast cancer

Cecile A. Lengacher, Versie Johnson‐Mallard, Janice Post‐White et al. · Psycho-Oncology · 2009 · 517 citations

Medicine, Oncology, Radiation Oncology +17

Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation

Jared Ehrhart, Demian Obregon, Takashi Mori et al. · Journal of Neuroinflammation · 2005 · 374 citations · Full text

Life Sciences, Neurobiology, Neuroscience +16

Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney: implication for renal function

Martin Kömhoff, H.-J. Gröne, Thomas Klein et al. · American Journal of Physiology-Renal Physiology · 1997 · 362 citations

Life Sciences, Developmental Biology, Physiology +13

Conditional and specific NF-κB blockade protects pancreatic beta cells from diabetogenic agents

Roy Eldor, Avner Yeffet, Ketty Baum et al. · Proceedings of the National Academy of Sciences · 2006 · 248 citations · Full text

Life Sciences, Cell Biology, Molecular Biology +17